1. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Issue 7 (August 2019) Authors: Hochmair, Maximilian; Weinlinger, Christoph; Schwab, Sophia; Naber, Jakob; Setinek, Ulrike; Krenbek, Dagmar; Urban, Matthias H.; Fabikan, Hannah; Watzka, Stefan; Koger, Renate; Fazekas, Andreas; Bitterlich, Erwin; Valipour, Arschang; Burghuber, Otto C. Journal: Anti-cancer drugs Issue: Volume 30:Issue 7(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗